Please login to the form below
AMNOG – One Year On...
A review of the impact of new pricing and reimbursement arrangements in Germany
Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.
The expert panel includes
- Justus Dehnen, Pricing and Market Access Leader, Germany
- Olaf Zweig, Principal, Global Health Practice, Berlin
Featured jobs
- Senior Brand Manager - Harlow
- Competitive
- Sales Manager - Media Publishing – Cheshire
- 25,000 to 35,000 per annum
- UK Marketing Director
- 80,000 to 100,000 per annum
- Group Account Director –Healthcare Advertising
- Neg
Subscribe to our email news alerts
- Achieving an aligned business intelligence capability - fact or fiction?
- Boehringer Ingelheim and Lilly launch diabetes education campaign
- GSK to set up online system for trial data requests
- Former Google chief launches online cancer forum
- Global biosimilars market to reach $2.45bn in 2013
- Value-based pricing "not in patient interest"
PMHub
Add my companyRed Door Communications
Red Door Communications (RDC) is a future-thinking consultancy dedicated to optimising communications between organisations with a health-related brand, service or ...
Latest intelligence
- How can pharma deliver returns on increased digital investment?
- Independent online professional networks work best as part of a multi-channel campaign ...
- The impact of Hollande's healthcare reforms in France
- A tougher environment for pharma, with market access and regulatory challenges...
- A guide to developing customer-centred, multichannel marketing
- Find out how a balanced approached to multichannel marketing could benefit your brand - the customer's agenda is just as important as Pharma's and needs to be listened to in ...
Quick links
